albutrepenonacog alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
blood factor IX 5189 1357448-54-4

Description:

MoleculeDescription

Synonyms:

  • albutrepenonacog alfa
  • idelvion
derived from recombinant factor IX and recombinant human albumin; used to treat hemophilia B
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 5, 2016 EMA CSL Behring GmbH
Sept. 28, 2016 PMDA CSL Behring K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hereditary factor IX deficiency disease indication 41788008 DOID:12259




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
A57KX1VL5P UNII
D10770 KEGG_DRUG
C4084478 UMLSCUI
DB13884 DRUGBANK_ID
9700 INN_ID
241551 MMSL
718928008 SNOMEDCT_US
781170000 SNOMEDCT_US
1743992 RXNORM
C000618231 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None